A method to quantify intracellular glycation in dermal fibroblasts using liquid chromatography coupled to fluorescence detection -Application to the selection of deglycation compounds of dermatological interest.
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Introduction
The glycation process, discovered by Maillard in 1912 [1] , is a non-enzymatic transformation involving reducing sugars and amino-acids residues of proteins, leading to the formation of a complex and heterogeneous group of compounds named advanced glycation end products (AGEs). More precisely, the process of glycation involves first the reaction of an ose (mainly glucose) with an amine group of a protein amino acid (like lysine or arginine), to form a Schiff base. An Amadori molecular rearrangement then leads to the irreversible formation of AGEs by successive cyclisation and oxidation reactions ( Fig. 1.) . Due to the various reactions leading to their creation, multiple AGEs have been detected in tissues, and can be divided into three categories: fluorescent AGEs forming reticulations between proteins (for example: pentosidine, crossline), nonfluorescent AGEs forming reticulations between proteins (for example: glyoxal-lysine dimer (GOLD), methylglyoxallysine dimer (MOLD)), and fluorescent or non-fluorescent AGEs forming adducts on proteins (for example: N-ε-carboxymethyllysine (CML), pyrraline) [2] .
AGEs accumulate during the lifetime in whole body including blood plasma, extracellular fluids and cells [3] . Consequently, they are considered as the main causing agent of numerous age-related diseases [4] such as diabetic vascular complications [5] , atherosclerosis [6] or Alzheimer's disease [3, 7] . Long lifespan proteins of the body like hemoglobin, collagen or elastin, are known targets of irreversible modifications due to AGEs formation [4] . Extracellular proteins cross-linking leads to cell growth inhibition, impaired cell adhesion and tissue dysfunction [8] . But AGEs are also formed inside cells, causing damages by generation of reactive oxygen species (ROS) [9] . They bond to the   121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180   4 Receptor of Advanced Glycation End products (RAGE) [10, 11] , thus increasing inflammation mediator release via the NF-κB pathway [12] . Activated inflammatory and oxidative cascades lead to the formation of new AGEs in cells. Moreover, excessive ROS levels affect intracellular detoxification systems like the proteasome, as well as other enzymes involved in cellular repairing. All this leads to a decrease in the antioxidative and repair potential of cells [11] . The overall negative effects of AGEs in cells lead to tissue and organ dysfunction [13] .
The glycation process does not spare the skin. AGEs have been shown to accumulate in the dermis and epidermis [14, 15] . Carboxymethyl-lysine (CML) and pentosidine are the most common AGEs in the skin [15] . Aesthetic consequences due to glycation are stiffening of the dermis leading mainly to collapsing of the skin, wrinkles formation, skin tone yellowing and emergence of brown spots, as it can be seen in diabetic patients [16, 17] . Most compounds on the market act by preventing the binding between sugars and proteins, or by reversing the first reversible steps of the glycation reaction. But there are only a few compounds that can reduce the number of final AGEs accumulated in the body [18] . Consequently, there is a growing dermatological, cosmetic and therapeutic interest in finding compounds able to get rid of AGEs accumulated in the skin.
However, most of the methods reported in the literature were used to detect and quantify glycation in food [19, 20] , human urine, plasma or serum [21] [22] [23] [24] , or in tubo formed AGEs by mixing a single protein with one reducing sugar [25, 26] . In the skin, studies mainly focus on extracellular proteins modified by glycation [27, 28] and not directly on the final AGEs formed at the end of the process. Few methods were reported in the literature to quantify glycation in skin cells, which are suitable with the screening of a very large number of drug candidates .   181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240   5 The goal of this work was to develop a reliable method able to detect and quantify intracellular AGEs naturally formed and accumulated in human cells upon aging, without using any AGE inducers. The level of AGEs was evaluated by measuring the characteristic autofluorescence of many AGEs [21, 29] and of particular pentosidine [30] . The developed method consist of the analysis of cell lysates using an HPLC system coupled with a fluorescence detector, in by-pass mode to allow a direct measurement of fluorescence using several wavelengths in the same time. The current article provides a detailed description of the technique, and demonstrates how it can be used to screen a large number of natural extracts in order to find new deglycation compounds capable of reducing the intracellular glycation in human fibroblasts.
Material and Methods

Chemical and reagents
Primary normal human dermal fibroblasts (NHDF) derived from a 54-years-old woman skin tissue were purchased from Promocell and cultured according to the supplier's instructions in fibroblasts growth medium2 (Promocell GmBH, Heidelberg, Germany). 
Natural extracts
A library of 269 ethyl acetate extracts of symbiotic microorganisms was used for this study [31, 32] . Their cytotoxicity have been tested against MRC-5, MDA-MB-435 cell lines. The extracts devoid of toxicity were then tested on primary dermal fibroblasts (NHDF) at three concentrations (10 µg/mL, 1 µg/mL and 0,1 µg/mL in DMSO; data available in Table S1 of supplementary material). The extracts having no toxic effect against NHDF at 1 µg/mL were used for the screening of their activity against intracellular AGEs.
Cell culture
Normal human dermal fibroblasts (NHDF) were grown in a humidified atmosphere of 5 % CO 2 at 37°C in fibroblasts growth medium2.
Method development
The NHDF were seeded at the density of 7000 cells/cm 2 on T25 flasks at day 0. 7 At day 1, the culture medium was supplemented with glyoxal (final concentration: 250 µM and 500 µM) for 48 hours. The control cells were treated with DMSO only. On day 3, at the end of treatment, culture medium was removed, and cells were washed with HEPES-Buffered saline solution (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) before adding fresh culture medium. Cells were cultivated for another 48 hours before being harvested on day 5 with Trypsine-EDTA solution. Cells were counted using an Automated Cell counter TC20 (BioRad Laboratories, Hercules, CA, U.S.A) and their pellets were kept at -20°C until use. Experiments were done in duplicate.
Application: Screening of natural extracts
The NHDF were seeded at the density of 7000 cells/cm 2 on 24-well-plates at day 0.
At day 1, the extracts were added in the culture medium (final concentration: 1 µg/mL) for 24 hours. Each experiment was conducted in duplicate. The control cells were treated with DMSO only. On day 2, after 24 hours of treatment, culture medium was removed, and cells were washed with HEPES-BSS solution before adding fresh culture medium. Cells were cultivated for an additional 48 hours before being harvested on day 4 with a Trypsine-EDTA solution. Cells were counted, freezed and stored at -20°C until use.
Cell lysis
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HPLC/Fluorescence method:
Sample preparation for HPLC/fluorescence
The day of the analysis, cell lysates were diluted three times with PBS 1X, filtered, and put into an HPLC insert vial. HPLC vials were kept at 4°C within the HPLC autosampler during all the experiment.
HPLC/Fluorescence analysis
For the analysis of the cell lysates, a Waters 2690/S separation module HPLC system coupled with a Waters W2475 fluorescence detector was used (Waters Corporation, Guyancourt, France). Since no separation was required, a by-pass was set-up instead of the column. Wavelengths on the fluorescence detector were set at λ ex = 370 nm / λem = 445 nm for measuring global AGEs amount, and at λ ex = 335 nm / λ em = 385 nm for measuring particular pentosidine amount, as previously described [21, 29, 30] .
Mobile phase used was 100 % milliQ H 2 O at a flow rate of 0.5 mL/min. Run length was 1 minute. Cell lysates (6 µL) were injected in triplicate, and a blank (water) was injected every 8 runs to confirm that no fluorescence accumulated in pipes.
Results analysis
Fluorescence picks were automatically integrated using Empower software (Waters Corporation, Guyancourt, France). Picks areas were analyzed and correspond to the cell lysate fluorescence value expressed in arbitrary units.
To allow the comparison between treatments, the fluorescence values were normalized for 1000 cells. 421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480   9 NHDF were plated on glass coverslips set into a 24-wells-plate and cultured in standard conditions as described above. On day 4, the fibroblasts were fixed with 2 % paraformaldehyde (500 µL) for 12 minutes at room temperature, permeabilized with 0.2 % TritonX-100 (500 µL) for 10 minutes and finally blocked with 5 % BSA, 0.2 % Tween-20 (500 µL) for further 10 minutes. Cells were then incubated with the primary antibody anti-CML (mouse) at a concentration of 7 µg/mL (30 µL) at 4°C overnight, Exposition : 300ms ; Laser power: 25%). Images are recorded using a Z stack, allowing fluorescence to be recorded at different positions in the cell. Five images were recorded by coverslips (ten pictures per treatment condition). All pictures were taken with the same microscope parameters. Fluorescence quantification on the images was done using ImageJ software.
CML immunofluorescence
Statistical analysis
Data were presented as mean ± standard error of the mean. The mean data were analyzed with one-way analysis of variance (one way ANOVA) followed by Dunnett's multiple comparison test. A P < 0.05 was considered to be significant. 481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540 To determine the reproducibility of the method, we calculated the relative standard deviation (RSD) for triplicates of the same sample, and biological duplicates of the same treatment (data available in Table S2 of supplementary material).
Method validation
Results
Method development
We first examined whether the proposed approach was able to detect and quantify the variations in the amount of AGEs and pentosidine in lysates of fibroblasts treated with 250 µM and 500 µM of glyoxal for 48 hours.
Glyoxal is a dicarbonyl formed in vivo mainly by auto-oxidation of reducing sugars and by lipid peroxidation. Both highly reactive carbonyl groups of glyoxal react with the amino groups of proteins to form AGEs as previously reported [33] [34] [35] .
Lysates of glyoxal treated cells and lysates of untreated controls were injected in triplicate in the HPLC system in by-pass mode, using MilliQ H 2 O as mobile phase, and the signal was recorded with a fluorescence detector using two sets of wavelengths for the simultaneous detection of AGEs (λ ex = 370 nm / λ em = 445 nm) and pentosidine (λ ex = 335 nm / λ em = 385 nm). The use of the HPLC system allows the analysis of small amounts of samples, with good reproducibility. The fluorescence spectra of pentosidine recorded in control cells lysate (triplicate) are presented in Figure 2 . The fluorescence value corresponds to peak integration value. To allow a reliable comparison between the treatments, the number of cells harvested at the end of the cell culture was counted, and the fluorescence values were normalized for 1000 cells. Table I , the treatment of fibroblasts with glyoxal increases significantly the fluorescence detected in cell lysates for both AGEs and pentosidine, in a dose-dependent 541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600 11 manner. A 1.3-fold and 2.2-fold increase in the amount of intracellular AGEs present in cells treated respectively with 250 µM and 500 µM of glyoxal for 48 hours, compared to controls was observed. For pentosidine, a 1.4-fold and 2.6-fold increase in cells treated respectively with 250 µM and 500 µM of glyoxal was detected.
As shown in
To valid these findings, we analyzed the level of carboxymethyl-lysine (CML) by immunocytochemistry in cells treated with 500 µM of glyoxal for 48 hours (Fig. 3.) . CML is an AGE forming adducts on proteins. Quantification of the immunofluorescence signal on images taken by confocal photonic microscopy shows that the intracellular CML content was indeed significantly higher in cells treated with glyoxal (1.57± 0.07 increase compared to non-treated control cells).
Application: The effect of natural products on the amount of intracellular pentosidine
As the developed method was able to detect variations in the content of AGEs in cells treated with different concentrations of glyoxal, we used it to screen eighty natural extracts and evaluate their potential to reduce the quantity of intracellular AGEs and pentosidine in human skin cells. Treatment of fibroblasts with extracts was done for 24 hours, in biological duplicate. The intracellular AGEs and pentosidine level was recorded by HPLC with fluorescence detector as described above. Aminoguanidine, an AGE inhibitor compound, was chosen as control. Table II show the results of twentythree of the extracts as the mean amount of pentosidine in cells compared to control.
The screening conducted in biological duplicates showed that aminoguanidine did not reduce the intracellular amount of pentosidine. However, among the eighty natural extracts, seven of them were shown to significantly reduce the intracellular content of 12 pentosidine in dermal fibroblasts. SNB-GTC2701 was the most active extract, reducing intracellular pentosidine content by 32 % in fibroblasts after 24 hours of treatment at 1 µg/mL.
Reproducibility
The reproducibility of the method was evaluated taking into account the triplicates of the same sample and biological duplicates of the same treatment.
The relative standard deviations of samples (RSD) between the triplicates of the same sample ranged within 10 % (except for treatment SNB-CN76) for AGEs and for pentosidine (Table S2 ). RSD calculated between biological duplicates showed good reproducibility as well (< 10 %). According to these results, the method can be considered as robust.
Discussion
The present method was developed to quantify the amount of intracellular AGEs and pentosidine in human dermal fibroblasts lysates, using their characteristic autofluorescent properties.
To develop the method, we used glyoxal treated fibroblasts. Glyoxal is mainly produced during the autooxidation of reducing sugars, and is a source of macromolecular damage in cells. Treatment of fibroblasts with glyoxal was shown to induce a senescent phenotype in vitro, and to lead to an increase of AGEs levels, thus providing a model of accelerated cellular aging [33] .
Results obtained with the developed method confirmed that glyoxal induces a change in the AGE content in fibroblasts. Moreover, the HPLC-fluorescent method was efficient to detect and quantify these changes. 661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720 13 Besides, by analyzing the results obtained during the development phase, we noticed that the glycation level of the non-treated dermal fibroblasts obtained from a 54 years old donor was high enough to be easily detected and quantified by the HPLC coupled with fluorescence method. In fact, AGEs accumulates in vivo during normal aging, and the detection of naturally occurring AGEs in fibroblasts with our method was of high interest for the next step of our project. This allowed us to screen the natural extracts library on cells that have not undergone glyoxal treatment, thus enabling the screening to be performed under conditions closest to the biological conditions in vivo.
During the screening, aminoguanidine was chosen as a control compound. This molecule works as a scavenger of reactive dicarbonyl intermediates in the Maillard reaction, therefore inhibiting AGE formation. Our results showed that aminoguanidine did not reduce the pentodisine level in fibroblasts. This finding is in line with published data on its mode of action preventing the condensation of reducing sugars with aminoacids residues, or inhibiting the first reversible reaction of the glycation process [36] .
We provide new evidence that aminoguanidine is not able to target AGEs at their final stage.
Among eighty natural extracts tested, seven of them showed positive results on pentosidine, significantly reducing its content in dermal fibroblasts after 24 hours of treatment. Comparing these results with those of aminoguanidine, we hypothesize that the mechanism of action of the tested active extracts might be linked to a possible activation or inhibition of specific biological pathways. Literature shows that AGE receptor (AGER) subunit AGER-1 (OST-48) binds to AGEs, triggering endocytosis and elimination of AGEs by cells, while this receptor does not bind to early glycation products like Amadori products [37] [38] [39] . Pentosidine can be degraded through this mechanism. We observed by western blot using a specific AGER-1 antibody that AGER-1 721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780 14 was overexpressed in cells treated with three of the active extracts ( Figure S1 ).
Although further investigations will be necessary, it is possible that the active extracts trigger a natural cell detoxification mechanism.
Due to the dermatological interest of finding compounds able to decrease the amount of formed AGEs in skin, an effort was made to make the assay more rapid and as simple as possible, allowing the screening of a large number of candidates in one time.
The screening of a large number of substances in a biological test requires cultivating cells in large amounts. But miniaturization of biological tests into multiwall plates lower the available quantity of samples to be analyzed. The main advantage of using an HPLC system is to benefit from the auto sampler allowing precise sampling of small amounts like few µL. This allowed us to miniaturize our biological screening into 24-wells plates, and so to decrease the amount of cells to be cultivated as well as the extract quantity to be applied as treatment.
Conclusion
The method described in this article allows detecting and quantifying intracellular levels of AGEs in human dermal fibroblasts. It is reliable, reproducible, simple and can be performed at rather low-cost. The use of HPLC coupled to fluorescence detection has many advantages. First, the fluorescence detection at two wavelengths at the same time reduces the quantity of sample required for analysis (6 µL per injections), allowing culture of cells in 24-wells plates. Then, once the cells harvested, one requires only a few steps of sample preparation. Finally, the automatic injection of the samples in a short one-minute run, with good reproducibility between technical and biological replicates, makes it suitable for the rapid and reliable screening of a large number of samples .   781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840 15 Contrary to commonly used methods i.e. in tubo tests employing one reducing sugar and one protein or methods targeting extracellular proteins modified by glycation, our experimental approach allows detection and quantification of intracellular AGEs formed and accumulated during aging in cells without induction of glycation.
Eventually, the method was applied to test natural extracts and revealed the potential of some of them to reduce the amount of AGEs naturally accumulated in cells with aging, thus suggesting that new deglycation compounds of dermatological and cosmetic interest may be discovered. The mode of action of the active extracts needs to be further characterized but seems to involve complex biological reactions. Thus, the molecules responsible for the activity will be characterized after bioguided isolation.
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Concentrations have been normalized relatively to the negative control, for 1000 cells.
Significance levels when compared to negative control were calculated by one-way ANOVA followed by Dunett's multiple comparison test *** P < 0.001 compared to control. Overexpression of AGER-1 in fibroblasts treated with extracts SNB-GSS07, SNB-GSS04 and SNB-CN13 at 1µg/mL during 24 hours.
Treatment
AGEs expression ± SD Pentosidine ± SD
Protocol:
Cells were collected and solubilized in RIPA lysis buffer. Protein concentrations were determined using the BCA method. Equal amount of proteins (26 µg) were separated on SDS-PAGE and transferred on 0.45 µm PVDF membranes. The primary antibodies used were: monoclonal anti-vinculin antibody produced in mouse (Sigma-Aldrich #V9131), anti-DDOST (AGER-1) antibody produced in rabbit (Sigma-Aldrich #D6820). The following secondary antibodies were used: anti-mouse IRDye 800CW and anti-rabbit IRDye 680LT (LI-COR). Membranes were scanned with an Odyssey Imaging System (LI-COR). Quantification was performed using ImageJ software. Unnecessary lanes were cut off and demarcated using black line in the following figure.
Results: Figure S1 . Overexpression of AGER-1 in fibroblasts treated with extracts SNB-GSS07, SNB-GSS04 and SNB-CN13 at 1µg/mL during 24 hours. (A) Total protein extracts of treated and control fibroblasts were analysed by western blotting using anti-AGER-1 antibody. Vinculin was uses as loading control. (B) Quantification of AGER-1 expression in cells (date shown in A) and expressed as percentage of control.
